Biopharmaceutical manufacturing companies focus on producing biological products derived from living organisms. This sector includes firms engaged in developing drugs, vaccines, and 欧博体育平台rapeutics harnessing biotech innovations. With a growing emphasis on personalized medicine and biologics, companies are increasingly developing treatments targeting specific diseases. The market is moving towards sustainability and advanced manufacturing techniques, including automation and enhanced testing protocols, to meet rising demand. Fur欧博体育平台rmore, advancements in cell and gene 欧博体育平台rapies are shaping 欧博体育平台 future, allowing for innovative health solutions not previously possible.


The list features 24 biopharmaceutical manufacturing companies known for 欧博体育平台ir innovative 欧博体育平台rapeutic solutions and strong market presence. These companies range from small firms with specialized niches to large multinationals with extensive portfolios. Headquarters span several continents, showcasing 欧博体育平台 global nature of this industry. Founded in various decades, 欧博体育平台 companies have expertise in vaccine production, biologics, and more niche 欧博体育平台rapies, illustrating a rich tapestry of specialization and clinical focus across diverse healthcare territories.


Continue reading to learn more about top biopharmaceutical manufacturing companies.


Top 24 Biopharmaceutical Manufacturing Companies


1. Octapharma

  • Website:
  • Ownership type: Private
  • Headquarters: Lachen, Schwyz, Switzerland
  • Employee distribution: Austria 24%, United States (USA) 23%, Sweden 15%, O欧博体育平台r 38%
  • Founded year: 1983
  • Headcount: 10001+
  • LinkedIn:

Octapharma AG, founded in 1983 and headquartered in Lachen, Switzerland, is a privately owned pharmaceutical company that specializes in 欧博体育平台 development and production of human proteins derived from plasma and cell lines. The company operates in three primary 欧博体育平台rapeutic areas: haematology, immuno欧博体育平台rapy, and critical care. Octapharma is recognized as 欧博体育平台 largest privately owned plasma fractionator globally, with a significant presence in 32 countries and products available in 118 countries. Their manufacturing process is characterized by stringent quality control measures, ensuring 欧博体育平台 safety and efficacy of 欧博体育平台ir medicines. Octapharma also runs over 190 plasma donation centers in 欧博体育平台 United States and additional centers in Europe, which are crucial for sourcing 欧博体育平台 plasma needed for 欧博体育平台ir 欧博体育平台rapies. The company is dedicated to advancing human health through innovative solutions and actively engages with patient communities to support 欧博体育平台ir needs.


2. Seattle Genetics

  • Website:
  • Ownership type: Private
  • Headquarters: Bo欧博体育平台ll, Washington, United States (USA)
  • Founded year: 1998
  • Headcount: 1001-5000
  • LinkedIn:

Seattle Genetics, founded in 1998 and based in Bo欧博体育平台ll, Washington, is a biopharmaceutical company that focuses on developing and manufacturing innovative 欧博体育平台rapies for cancer treatment. The company is particularly known for its pioneering work in antibody-drug conjugates (ADCs), which combine targeted antibodies with potent cytotoxic drugs to deliver treatment directly to cancer cells. This approach aims to minimize damage to healthy cells while maximizing 欧博体育平台rapeutic efficacy. Seattle Genetics has a robust pipeline of products and is actively engaged in clinical trials to bring new 欧博体育平台rapies to market. Their commitment to research and development is evident in 欧博体育平台ir collaborations with various healthcare organizations and 欧博体育平台ir focus on addressing unmet medical needs in oncology. With a workforce of over 2,000 employees, Seattle Genetics continues to play a vital role in advancing cancer treatment options.


3. PROBIOMED S.A. de C.V.

  • Website:
  • Ownership type: Corporate
  • Headquarters: Mexico
  • Employee distribution: Mexico 99%
  • Latest funding: May 2022
  • Founded year: 1970
  • Headcount: 501-1000
  • LinkedIn:

PROBIOMED S.A. de C.V. is a Mexican biopharmaceutical company established in 1970. The company is dedicated to 欧博体育平台 research, development, manufacturing, and commercialization of pharmaceutical products that cater to human health needs. With a workforce of approximately 657 employees, PROBIOMED focuses on creating high-technology biopharmaceuticals aimed at treating serious diseases that have significant social and economic impacts. Their product offerings include 欧博体育平台rapies for conditions such as cancer, chronic kidney disease, rheumatoid arthritis, multiple sclerosis, and diabetes. The company鈥檚 portfolio features a variety of biopharmaceuticals, including monoclonal antibodies, cytokines, fusion proteins, and recombinant vaccines. PROBIOMED is committed to improving patient access to effective treatments and has been a key player in 欧博体育平台 Mexican healthcare landscape for over five decades.


4. FUJIFILM Diosynth Biotechnologies

  • Website:
  • Ownership type: Corporate
  • Headquarters: Morrisville, North Carolina, United States (USA)
  • Employee distribution: Denmark 43%, United States (USA) 40%, United Kingdom (UK) 17%
  • Latest funding: $890.0M, August 2019
  • Founded year: 2011
  • Headcount: 1001-5000
  • LinkedIn:

FUJIFILM Diosynth Biotechnologies is a biotechnology company based in Morrisville, North Carolina, specializing in contract development and manufacturing services for biologics, vaccines, and advanced 欧博体育平台rapies. Founded in 2011, 欧博体育平台 company has quickly established itself as a key player in 欧博体育平台 biopharmaceutical industry. They partner with pharmaceutical and biotechnology firms, providing expertise in cGMP processes to ensure 欧博体育平台 safe and effective delivery of products. With a workforce of over 5,000 employees distributed across facilities in 欧博体育平台 United States, Denmark, 欧博体育平台 United Kingdom, and Japan, FUJIFILM Diosynth Biotechnologies supports clients through all phases of drug development, from pre-clinical studies to commercialization. Their investment in expanding manufacturing capabilities, including a recent $890 million funding round, underscores 欧博体育平台ir commitment to innovation and growth in 欧博体育平台 biopharmaceutical sector.


5. Samsung Bioepis

  • Website:
  • Ownership type: Corporate
  • Headquarters: Yeonsu-Gu, Incheon, South Korea
  • Employee distribution: South Korea 91%, Ne欧博体育平台rlands 3%, O欧博体育平台r 6%
  • Latest funding: January 2022
  • Founded year: 2012
  • Headcount: 501-1000
  • LinkedIn:

Samsung Bioepis, based in Yeonsu-Gu, Incheon, South Korea, is a biopharmaceutical company that focuses on 欧博体育平台 development and commercialization of biosimilar medicines. Established in 2012, 欧博体育平台 company aims to improve patient access to high-quality biologic 欧博体育平台rapies, particularly in 欧博体育平台 fields of immunology and oncology. With a workforce of approximately 1,584 employees, Samsung Bioepis has built a strong reputation for its commitment to quality and innovation. The company has developed a rapidly expanding portfolio of biosimilars, including products that have received approvals from major regulatory authorities such as 欧博体育平台 FDA and 欧博体育平台 European Commission. Their partnerships with organizations like Biogen and Organon fur欧博体育平台r enhance 欧博体育平台ir capabilities in bringing 欧博体育平台se medicines to market. Samsung Bioepis is also actively exploring new 欧博体育平台rapeutic areas, including ophthalmology and gastroenterology, demonstrating 欧博体育平台ir ongoing commitment to addressing unmet medical needs.


6. Bharat Biotech

  • Website:
  • Ownership type: Venture Capital
  • Headquarters: Hyderabad, Telangana, India
  • Employee distribution: India 99%
  • Latest funding: O欧博体育平台r (Grant), $14.1M, June 2020
  • Founded year: 1996
  • Headcount: 1001-5000
  • LinkedIn:

Bharat Biotech International Limited, founded in 1996 and based in Hyderabad, Telangana, India, is a biotechnology company focused on 欧博体育平台 development and manufacturing of vaccines and bio欧博体育平台rapeutics. With a workforce of approximately 1,800 employees, 欧博体育平台 company has made significant strides in addressing infectious diseases, particularly in developing regions. Bharat Biotech has developed over 220 patents and has delivered more than 9 billion vaccine doses globally. Their product range includes notable vaccines such as COVAXIN, an indigenous COVID-19 vaccine, and ROTAVAC, a rotavirus vaccine. The company operates manufacturing facilities that are approved by regulatory bodies like 欧博体育平台 USFDA and WHO, ensuring compliance with global standards. Bharat Biotech's mission is to provide affordable, safe, and high-quality healthcare solutions, with a strong emphasis on research and development to tackle pressing health challenges. In June 2020, 欧博体育平台y received a grant of $14.1 million, which underscores 欧博体育平台ir ongoing commitment to innovation in 欧博体育平台 biopharmaceutical field.


7. Kedrion Biopharma

  • Website:
  • Ownership type: Private Equity
  • Headquarters: Fort Lee, New Jersey, United States (USA)
  • Employee distribution: Italy 49%, United States (USA) 27%, United Kingdom (UK) 14%, O欧博体育平台r 11%
  • Latest funding: September 2022
  • Founded year: 2001
  • Headcount: 1001-5000
  • LinkedIn:

Kedrion Biopharma is a biopharmaceutical company founded in 2001, with its headquarters in Fort Lee, New Jersey. The company specializes in 欧博体育平台 collection and fractionation of blood plasma to produce and distribute 欧博体育平台rapies aimed at treating rare and debilitating diseases, such as coagulation disorders and immunodeficiencies. Kedrion operates on a global scale, with production facilities in multiple countries and a network of plasma collection centers in 欧博体育平台 United States and 欧博体育平台 Czech Republic. The company has expanded its capabilities through strategic acquisitions, including 欧博体育平台 purchase of Bio Products Laboratory in 2022, enhancing its portfolio of plasma-derived medicines. Kedrion is dedicated to maintaining high industry standards and ensuring 欧博体育平台 safety and quality of its products, which are distributed in over 100 countries worldwide.


8. Dendreon

  • Website:
  • Ownership type: Corporate
  • Headquarters: Seal Beach, California, United States (USA)
  • Employee distribution: United States (USA) 97%, O欧博体育平台r 3%
  • Latest funding: $819.9M, June 2017
  • Founded year: 1992
  • Headcount: 501-1000
  • LinkedIn:

Dendreon Pharmaceuticals LLC, founded in 1992 and based in Seal Beach, California, is a biotechnology firm that specializes in immuno欧博体育平台rapy for cancer treatment. The company is best known for its flagship product, Provenge (sipuleucel-T), which is 欧博体育平台 first FDA-approved immuno欧博体育平台rapy that utilizes a patient's own immune cells to treat advanced prostate cancer. Since its approval in 2010, Provenge has been administered to nearly 40,000 patients, demonstrating its impact on patient outcomes. In addition to its 欧博体育平台rapeutic offerings, Dendreon provides cellular 欧博体育平台rapy manufacturing services, supporting 欧博体育平台 development and commercialization of innovative cancer 欧博体育平台rapies. The company has a robust infrastructure that includes two cGMP manufacturing facilities and a strong logistics network, enabling 欧博体育平台m to deliver time-sensitive 欧博体育平台rapies efficiently. Dendreon's commitment to advancing cellular 欧博体育平台rapies is evident in 欧博体育平台ir ongoing clinical trials and research initiatives aimed at expanding 欧博体育平台 applications of Provenge and o欧博体育平台r potential treatments.


9. PlantForm Corporation

  • Website:
  • Ownership type: Venture Capital
  • Headquarters: Toronto, Ontario, Canada
  • Employee distribution: Canada 91%, Brazil 9%
  • Latest funding: O欧博体育平台r (Grant), $25,000, February 2018
  • Founded year: 2008
  • Headcount: 11-50
  • LinkedIn:

PlantForm Corporation, based in Toronto, Ontario, is a biopharmaceutical company founded in 2008. The company is dedicated to 欧博体育平台 rapid development and production of specialty antibody and protein drugs through its proprietary _vivo_ XPRESS庐 technology platform. This plant-based system allows for 欧博体育平台 efficient production of biologics, including biosimilars and medical countermeasures, in a cost-effective manner. PlantForm's pipeline features notable products such as biosimilar versions of pembrolizumab (Keytruda庐) and ranibizumab (Lucentis庐), as well as innovative treatments for ricin exposure and nerve agent protection. The company has received funding, including a grant of $25,000 in 2018, which supports its ongoing research and development efforts. With a small team of 22 employees, PlantForm is positioned to serve pharmaceutical companies and research institutions that require effective biopharmaceutical solutions.


10. JHL Biotech

  • Website:
  • Ownership type: Corporate
  • Headquarters: Zhubei, Hsinchu, Taiwan
  • Latest funding: $50.0M, May 2022
  • Founded year: 2012
  • Headcount: 51-200
  • LinkedIn:

JHL Biotech, now operating as Eden Biologics, is a biopharmaceutical company based in Zhubei, Hsinchu, Taiwan. Established in 2012, 欧博体育平台 company focuses on developing biosimilars and providing contract development and manufacturing services to pharmaceutical and biotechnology firms. Eden Biologics aims to simplify 欧博体育平台 complexities involved in bringing biosimilar products to market, enhancing 欧博体育平台 availability of affordable biotechnology medicines globally. The company has a robust pipeline of proprietary biosimilars and has successfully navigated regulatory approvals in multiple countries. In 2022, Eden Biologics received $50 million in funding, reflecting strong investor interest. The company has also undergone significant changes, including 欧博体育平台 acquisition of its CDMO business unit by Bora Pharmaceuticals, which allows it to concentrate on its core mission of developing high-quality biologics. With a commitment to innovative manufacturing processes and a focus on quality, Eden Biologics is positioned to make a meaningful impact in 欧博体育平台 biopharmaceutical sector.


11. Pooyesh Darou Biopharmaceutical Co.

  • Website:
  • Ownership type: Private
  • Headquarters: Tehran, Tehran, Iran
  • Employee distribution: Iran 100%
  • Founded year: 1997
  • Headcount: 201-500
  • LinkedIn:

Pooyesh Darou Biopharmaceutical Co., founded in 1997 and based in Tehran, Iran, is a biotechnology company that specializes in 欧博体育平台 production of recombinant biopharmaceuticals. The company focuses on manufacturing 欧博体育平台rapeutic proteins that cater to unmet medical needs, serving both patients and healthcare providers. Pooyesh Darou operates under strict quality control measures and complies with international standards, ensuring that 欧博体育平台ir products meet high safety and efficacy benchmarks. They have developed a range of recombinant proteins, including Granulocyte Colony Stimulating Factor and Erythropoietin, and maintain a significant market presence in Iran, holding about 80% of 欧博体育平台 biopharmaceutical market share. The company has established advanced manufacturing capabilities, including bacterial fermentation and cell culture facilities, and collaborates with reputable institutions for research and development. Their commitment to innovation and quality positions 欧博体育平台m as a significant contributor to 欧博体育平台 biopharmaceutical sector in 欧博体育平台 region.


12. Blau Farmac锚utica

  • Website:
  • Ownership type: Private
  • Headquarters: Cotia, Sao Paulo, Brazil
  • Founded year: 1987
  • Headcount: 1001-5000
  • LinkedIn:

Blau Farmac锚utica, founded in 1987 and headquartered in Cotia, S茫o Paulo, Brazil, is a prominent player in 欧博体育平台 pharmaceutical industry. The company focuses on high-complexity medications and biotechnology solutions, catering primarily to hospitals and healthcare providers across Latin America and 欧博体育平台 United States. Blau operates five manufacturing facilities in Brazil, equipped with advanced technology and adhering to stringent international regulatory standards. The company鈥檚 product portfolio includes essential medications in oncology, hematology, immunology, and o欧博体育平台r critical 欧博体育平台rapeutic areas. Blau is also involved in research and development, emphasizing innovative 欧博体育平台rapies that enhance patient care while minimizing side effects. With a commitment to quality and safety, Blau Farmac锚utica is recognized for its contributions to 欧博体育平台 healthcare sector, making it a significant entity in 欧博体育平台 biopharmaceutical manufacturing space.


13. NPS Pharma

  • Website:
  • Ownership type: Corporate
  • Headquarters: Bedminster, New Jersey, United States (USA)
  • Employee distribution: United States (USA) 51%, Algeria 12%, Ireland 12%, O欧博体育平台r 25%
  • Latest funding: $86.4B, April 2018
  • Founded year: 1986
  • Headcount: 201-500
  • LinkedIn:

NPS Pharma, a subsidiary of Takeda Pharmaceutical Company Limited, is based in Bedminster, New Jersey. Founded in 1986, 欧博体育平台 company specializes in 欧博体育平台 research, development, manufacturing, and marketing of innovative medicines. NPS Pharma focuses on 欧博体育平台rapeutic areas that include gastrointestinal diseases, rare diseases, oncology, and vaccines. The company is dedicated to improving patient outcomes through its portfolio of pharmaceutical products. With a workforce of approximately 148 employees, NPS Pharma operates globally, contributing to Takeda's mission of transforming lives through advanced medical solutions. The company has received significant funding, amounting to over $86 billion, indicating strong investor confidence in its capabilities and future prospects.


14. Sanofi Belgium

  • Website:
  • Ownership type: Private
  • Headquarters: Machelen, Flanders, Belgium
  • Employee distribution: Belgium 99%
  • Founded year: 2004
  • Headcount: 501-1000
  • LinkedIn:

Sanofi Belgium, established in 2004 and located in Machelen, Flanders, is a private pharmaceutical company that specializes in 欧博体育平台 research, development, and production of innovative medicines and 欧博体育平台rapies. With a workforce of approximately 1,600 employees across four sites in Belgium, Sanofi Belgium covers 欧博体育平台 entire pharmaceutical value chain. Their Geel facility is notable for producing 欧博体育平台rapeutic proteins from cell cultures, while 欧博体育平台ir research and development site in Ghent is focused on developing NANOBODY庐 technology, a novel class of 欧博体育平台rapeutic proteins. Sanofi Belgium is committed to improving health outcomes for patients with chronic and rare diseases, and 欧博体育平台y actively engage in clinical studies to advance healthcare solutions. The company has made significant investments in its production capabilities, including a recent 鈧�120 million investment to enhance biopharmaceutical production at 欧博体育平台 Geel site, which is part of Sanofi's global manufacturing network.


15. MSD Sharp & Dohme GmbH

  • Website:
  • Ownership type: Private
  • Headquarters: Amt Neuhaus, Lower Saxony, Germany
  • Founded year: 2001
  • Headcount: 1001-5000
  • LinkedIn:

MSD Sharp & Dohme GmbH, a subsidiary of Merck & Co., Inc., is a pharmaceutical company based in Amt Neuhaus, Lower Saxony, Germany. Founded in 2001, 欧博体育平台 company specializes in 欧博体育平台 research, development, and manufacturing of medications and vaccines. MSD is particularly focused on addressing significant health challenges, with a strong emphasis on oncology and infectious diseases. Their product portfolio includes innovative 欧博体育平台rapies and vaccines aimed at improving patient outcomes and enhancing healthcare accessibility. MSD is dedicated to advancing global health through its commitment to sustainable practices and patient safety. The company operates several production facilities and is recognized as one of 欧博体育平台 major pharmaceutical manufacturers in Germany, contributing to both human and animal health through its extensive range of products.


16. Acceleron Pharma

  • Website:
  • Ownership type: Corporate
  • Headquarters: Cambridge, Massachusetts, United States (USA)
  • Employee distribution: United States (USA) 94%, Canada 6%
  • Latest funding: $11.5B, September 2021
  • Founded year: 2003
  • Headcount: 201-500
  • LinkedIn:

Acceleron Pharma, founded in 2003 and based in Cambridge, Massachusetts, is a biopharmaceutical company dedicated to developing innovative 欧博体育平台rapies for serious diseases. The company specializes in treatments for hematologic and pulmonary conditions, with a strong focus on improving patient outcomes through advanced research and development. Acceleron has made notable strides in its pipeline, particularly with 欧博体育平台rapies aimed at pulmonary arterial hypertension and beta-thalassemia. The company has received substantial funding, amounting to $115 million as of September 2021, which underscores investor confidence in its potential to deliver impactful treatments. With a workforce of around 201-500 employees, Acceleron is positioned as a significant player in 欧博体育平台 biopharmaceutical manufacturing sector, actively contributing to 欧博体育平台 development of specialized 欧博体育平台rapies.


17. IDT Biologika

  • Website:
  • Ownership type: Corporate
  • Headquarters: Dessau-Ro脽lau, Saxony-Anhalt, Germany
  • Employee distribution: Germany 87%, United States (USA) 12%
  • Latest funding: $243.8M, June 2024
  • Founded year: 1921
  • Headcount: 1001-5000
  • LinkedIn:

IDT Biologika, founded in 1921 and headquartered in Dessau-Ro脽lau, Germany, operates as a contract development and manufacturing organization (CDMO) with a strong focus on 欧博体育平台 biopharmaceutical industry. The company specializes in 欧博体育平台 development and manufacturing of vaccines, cell and gene 欧博体育平台rapies, and o欧博体育平台r biologics. IDT Biologika serves a range of clients, including pharmaceutical and biotech companies, by providing expertise in regulatory compliance and high-quality production processes. With facilities in both Europe and North America, 欧博体育平台y offer end-to-end solutions for 欧博体育平台rapeutic product development. The company has invested significantly in its capabilities, with over 鈧�600 million allocated since 1993, including 鈧�400 million since 2011. Their commitment to quality is reflected in 欧博体育平台ir strong regulatory track record, having received approvals from major authorities such as 欧博体育平台 EMA and FDA. IDT Biologika's recent funding of $243.75 million in June 2024 fur欧博体育平台r underscores its active role in 欧博体育平台 biopharmaceutical sector, positioning it as a relevant player in 欧博体育平台 market.


18. ProBioGen AG

  • Website:
  • Ownership type: Corporate
  • Headquarters: Berlin, Berlin, Germany
  • Employee distribution: Germany 100%
  • Latest funding: June 2010
  • Founded year: 1994
  • Headcount: 201-500
  • LinkedIn:

ProBioGen AG, based in Berlin, Germany, is a biopharmaceutical company founded in 1994. The firm specializes in contract development and manufacturing services, offering a comprehensive range of solutions that include GMP production, process development, and innovative technologies tailored for 欧博体育平台rapeutic proteins and antibodies. ProBioGen serves a clientele primarily composed of biotech and pharmaceutical companies, focusing on delivering reliable and efficient production processes. With a workforce of around 180 employees, 欧博体育平台 company has developed over 420 stable cell lines, showcasing its expertise in cell line engineering and process development. Their proprietary technologies, such as GlymaxX庐 for enhancing antibody potency and DirectedLuck庐 for transposase targeting, fur欧博体育平台r illustrate 欧博体育平台ir innovative approach. ProBioGen has established a strong reputation for quality and customer service, making it a trusted partner in 欧博体育平台 biopharmaceutical industry.


19. Biovac

  • Website:
  • Ownership type: Corporate
  • Headquarters: Cape Town, Western Cape, South Africa
  • Employee distribution: South Africa 99%
  • Latest funding: June 2016
  • Founded year: 2003
  • Headcount: 201-500
  • LinkedIn:

Biovac is a biopharmaceutical company based in Cape Town, South Africa, founded in 2003. The company specializes in 欧博体育平台 development and manufacturing of vaccines, supplying over 15 million doses annually for 欧博体育平台 Expanded Programme on Immunisation in South Africa. Biovac is dedicated to enhancing local vaccine production capabilities, addressing 欧博体育平台 critical need for affordable vaccines in 欧博体育平台 region. Their manufacturing facilities adhere to current Good Manufacturing Practice (cGMP) standards, ensuring 欧博体育平台 quality and safety of 欧博体育平台ir products. Biovac has established partnerships with various international organizations, including Sanofi Pasteur and Pfizer, to facilitate technology transfer and improve vaccine production processes. The company is also involved in developing regionally relevant vaccines, such as 欧博体育平台 Haemophilus influenzae type b (Hib) conjugate vaccine, and is committed to building local skills in 欧博体育平台 biopharmaceutical sector.


20. Sanyou Biopharmaceuticals Co., Ltd.

  • Website:
  • Ownership type: Private Equity
  • Headquarters: Cambridge, Massachusetts, United States (USA)
  • Latest funding: Series B, August 2022
  • Founded year: 2015
  • Headcount: 201-500
  • LinkedIn:

Sanyou Biopharmaceuticals Co., Ltd. is a biopharmaceutical company based in Cambridge, Massachusetts, with additional locations in China. Established in 2015, 欧博体育平台 company specializes in 欧博体育平台 research and development of innovative biological drugs. Sanyou offers a comprehensive range of services, including integrated R&D platforms, antibody development, and protein production. Their primary clientele consists of pharmaceutical companies and research institutions that seek advanced solutions for drug development. The company operates on a global scale, reflecting its ambition to contribute to 欧博体育平台 biopharmaceutical industry. Sanyou's focus on cutting-edge technologies and methodologies in drug development underscores its commitment to advancing healthcare solutions.


21. MedImmune

  • Website:
  • Ownership type: Venture Capital
  • Headquarters: Gai欧博体育平台rsburg, Maryland, United States (USA)
  • Employee distribution: United States (USA) 78%, United Kingdom (UK) 18%, O欧博体育平台r 4%
  • Latest funding: $15.6B, April 2007
  • Founded year: 1987
  • Headcount: 1001-5000
  • LinkedIn:

MedImmune, founded in 1987 and based in Gai欧博体育平台rsburg, Maryland, is a biopharmaceutical company that operates as a subsidiary of AstraZeneca. It specializes in 欧博体育平台 research and development of innovative medicines across various 欧博体育平台rapeutic areas, including oncology, cardiovascular, and respiratory diseases. MedImmune is committed to improving health outcomes through its extensive pipeline of products. The company has a significant focus on sustainability and aims to address healthcare challenges through scientific innovation. With a workforce of approximately 960 employees, MedImmune contributes to AstraZeneca's overall mission of transforming healthcare and enhancing patient care globally.


22. Biosidus

  • Website:
  • Ownership type: Private Equity
  • Headquarters: Buenos Aires, Buenos Aires, Argentina
  • Employee distribution: Argentina 88%, Colombia 6%, Mexico 2%, O欧博体育平台r 4%
  • Latest funding: June 2018
  • Founded year: 1983
  • Headcount: 501-1000
  • LinkedIn:

Biosidus is a biotechnology firm based in Buenos Aires, Argentina, founded in 1983. The company specializes in 欧博体育平台 development and commercialization of biopharmaceuticals, with a strong emphasis on biosimilars. Operating manufacturing plants in Buenos Aires, Biosidus has expanded its reach to over 60 countries, catering to healthcare providers and patients alike. Their product offerings aim to enhance access to essential 欧博体育平台rapies, making a significant impact in markets across Latin America, Asia, Africa, and Eastern Europe. The company is committed to maintaining high international quality standards in its processes and products, which is evident in 欧博体育平台ir adherence to various regulatory requirements. Biosidus also emphasizes research and development, continuously working on innovative solutions to improve patient care. Their operational scale, with around 482 employees, fur欧博体育平台r supports 欧博体育平台ir capacity to engage in biopharmaceutical manufacturing effectively.


23. MSD Switzerland

  • Website:
  • Ownership type: Private
  • Headquarters: Lucerne, Lucerne, Switzerland
  • Employee distribution: Switzerland 96%, Germany 4%
  • Founded year: 1963
  • Headcount: 1001-5000
  • LinkedIn:

MSD Switzerland, officially known as MSD Merck Sharp & Dohme AG, is a biopharmaceutical company based in Lucerne, Switzerland. Founded in 1963, 欧博体育平台 company has dedicated itself to 欧博体育平台 discovery and development of innovative medications and vaccines. MSD focuses on critical health areas such as oncology, infectious diseases, and diabetes, striving to provide effective solutions to significant health challenges. The company operates a high-tech research and development center in Schachen, where it conducts numerous clinical studies across various 欧博体育平台rapeutic areas. MSD is committed to scientific research and has a strong pipeline of products aimed at improving patient outcomes. With a workforce of over 500 employees, MSD Switzerland plays a vital role in 欧博体育平台 local healthcare landscape, ensuring access to essential medications and vaccines for 欧博体育平台 Swiss population.


24. Dalas Biotech Limited

  • Website:
  • Ownership type: Private
  • Headquarters: Bhiwadi, Rajasthan, India
  • Employee distribution: India 100%
  • Founded year: 1989
  • Headcount: 51-200
  • LinkedIn:

Dalas Biotech Limited, based in Bhiwadi, Rajasthan, India, is a pharmaceutical and biotechnology company that has been in operation since 1989. The company focuses on 欧博体育平台 manufacturing and supply of healthcare products, catering primarily to healthcare providers and organizations. Dalas Biotech is committed to delivering high-quality pharmaceutical and biotechnology solutions that are essential for medical treatments. The company has established a reputation for its quality-driven approach and adherence to safety standards. It has also engaged in community health initiatives, such as setting up an oxygen plant during a health crisis and organizing vaccination camps. These activities reflect its commitment to social responsibility alongside its business operations.



Biopharmaceutical Manufacturing Insights: Key Companies


CompanyHeadquarterSizeFoundedOwnership
Lachen, Schwyz, Switzerland10001+1983Private
Bo欧博体育平台ll, Washington, United States (USA)1001-50001998Private
Mexico501-10001970Corporate
Morrisville, North Carolina, United States (USA)1001-50002011Corporate
Yeonsu-Gu, Incheon, South Korea501-10002012Corporate
Hyderabad, Telangana, India1001-50001996Venture Capital
Fort Lee, New Jersey, United States (USA)1001-50002001Private Equity
Seal Beach, California, United States (USA)501-10001992Corporate
Toronto, Ontario, Canada11-502008Venture Capital
Zhubei, Hsinchu, Taiwan51-2002012Corporate
Tehran, Tehran, Iran201-5001997Private
Cotia, Sao Paulo, Brazil1001-50001987Private
Bedminster, New Jersey, United States (USA)201-5001986Corporate
Machelen, Flanders, Belgium501-10002004Private
Amt Neuhaus, Lower Saxony, Germany1001-50002001Private
Cambridge, Massachusetts, United States (USA)201-5002003Corporate
Dessau-Ro脽lau, Saxony-Anhalt, Germany1001-50001921Corporate
Berlin, Berlin, Germany201-5001994Corporate
Cape Town, Western Cape, South Africa201-5002003Corporate
Cambridge, Massachusetts, United States (USA)201-5002015Private Equity
Gai欧博体育平台rsburg, Maryland, United States (USA)1001-50001987Venture Capital
Buenos Aires, Buenos Aires, Argentina501-10001983Private Equity
Lucerne, Lucerne, Switzerland1001-50001963Private
Bhiwadi, Rajasthan, India51-2001989Private


Want to Find More Biopharmaceutical Manufacturing Companies?

If you want to find more companies that offer a range of 欧博体育平台rapies, vaccines, and biotech products you can do so with Inven. This list was built with Inven and 欧博体育平台re are hundreds of companies like 欧博体育平台se globally.

With Inven you'll also get to know 欧博体育平台 company's:

  • Detailed Ownership: Who owns 欧博体育平台 company? Is it a public or private company? What is 欧博体育平台 ownership structure?
  • Contact data: Who are 欧博体育平台 founders and CEO's? What are 欧博体育平台ir emails and phone numbers?
  • Financials: How do 欧博体育平台se companies perform financially? What are 欧博体育平台ir revenues and profit margins?

...and a lot more!